Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017

Details for Mechanism ID: 17083
Country/Region: Papua New Guinea
Year: 2016
Main Partner: FHI 360
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $3,708,980 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $96,631
Care: TB/HIV (HVTB) $178,027
Laboratory Infrastructure (HLAB) $300,000
Strategic Information (HVSI) $394,830
Health Systems Strengthening (OHSS) $0
Testing: HIV Testing and Counseling (HVCT) $362,242
Sexual Prevention: Other Sexual Prevention (HVOP) $1,721,137
Treatment: Adult Treatment (HTXS) $656,113
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 25
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 20
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 100
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 50
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 50
GEND_GBV Number of people receiving post-GBV care 2017 50
GEND_GBV Number of people receiving post-GBV care 2017 150
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 16
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 19
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 1,072
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 2,157
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 750
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 1,543
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 1,857
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 3,700
HTS_TST Service Delivery Point (Facility): Other PITC 2017 1,857
HTS_TST Service Delivery Point (Facility): Other PITC 2017 3,700
HTS_TST Sum of Aggregated Age/Sex <15 2017 35
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 1,822
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 3,700
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 1,857
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 3,700
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 1
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 5
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 74
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 123
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 44
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 85
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 1,444
KP_PREV By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 416
KP_PREV By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 640
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2017 2,500
PP_PREV Aggregated Age/sex: 15+ Female 2017 792
PP_PREV Aggregated Age/sex: 15+ Male 2017 708
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 1,500
TB_SCREENDX Screened for TB by Age/Sex: <15 Female 2017 25
TB_SCREENDX Screened for TB by Age/Sex: <15 Male 2017 5
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 228
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 218
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 128
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 150
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 386
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 368
TX_CURR Aggregated Age/Sex: <15 Female 2017 6
TX_CURR Aggregated Age/Sex: <15 Male 2017 27
TX_CURR Aggregated Age/Sex: 15+ Female 2017 276
TX_CURR Aggregated Age/Sex: 15+ Female 2017 244
TX_CURR Aggregated Age/Sex: 15+ Male 2017 159
TX_CURR Aggregated Age/Sex: 15+ Male 2017 166
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 468
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 410
TX_CURR Sum of Aggregated Age/Sex <15 2017 33
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 435
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 410
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 468
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 410
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 1
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 4
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 68
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 111
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 40
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 76
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 113
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 187
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 113
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 187
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 14
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 50
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 13
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 45
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 8
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 27
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 5
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 18
TX_PVLS Numerator: Indication: Targeted 2017 13
TX_PVLS Numerator: Indication: Targeted 2017 45
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 9
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 30
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 5
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 20
TX_PVLS_den Denominator: Indication: Targeted 2017 14
TX_PVLS_den Denominator: Indication: Targeted 2017 50
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 6
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 53
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 86
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 30
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 58
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 90
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 144
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 100
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 160
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 59
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 96
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 33
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 64
Cross Cutting Budget Categories and Known Amounts Total: $3,884,867
Human Resources for Health $543,185
Key Populations: MSM and TG $1,641,881
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Monitoring and evaluation of MSM/TG programs
Key Populations: Sex Workers $883,555
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Monitoring and evaluation of SW programs
Gender: Gender Based Violence (GBV) $787,297
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Condoms: Policy, Tools, and Services $28,949